强生指今年疫苗产能可达10亿剂 料明年产量最多30亿剂
强生(JNJ.US)首席科学家Paul Stoffels预计,今年可生产10亿剂新冠疫苗,而至明年最多可扩至30亿剂。
他指,已准备3间厂房以生产疫苗所须的主要原料,以及在各地的7间厂房生产疫苗,以准备作疫苗的最後工序。
强生疫苗昨获得欧盟批准所紧急使用,成为第四间获批的疫苗。Paul Stoffels指,相信第二季可以向欧盟交付5,500万剂疫苗,不过目前最後工序方面是最大挑战。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.